The bill amends section 28-405 of the Revised Statutes Supplement, 2025, as part of the Uniform Controlled Substances Act, by designating several new substances as controlled, including various fentanyl analogs, synthetic opioids, and other complex chemical structures. Notable additions include "Brorphine," "Para-chlorofentanyl," and new entries under Schedule II and Schedule III such as ethylphenidate and dipentylone. The bill also clarifies that cannabidiol in FDA-approved drug products is excluded from these classifications, while expanding the list of controlled substances to include specific phenethylamines and tryptamines. Additionally, the bill introduces several new substances to Schedule IV, including Brexanolone, Lemborexant, Solriamfetol, Remimazolam, Serdexmethylphenidate, and Zuranolone, and psilocybin in its crystalline polymorph form as an FDA-approved pharmaceutical composition. It also outlines regulations regarding the sale and distribution of ephedrine, including quantity restrictions. The original section 28-405 is repealed, indicating a significant restructuring of the legal framework to enhance clarity and effectiveness in regulating controlled substances, while ensuring that legitimate uses, such as veterinary applications of xylazine, are not hindered.

Statutes affected:
Introduced: 28-401, 28-405
Final Reading: 28-405
Slip Law: 28-405